Impact of decreasing copayments on medication adherence within a disease management environment.
about
Can broader diffusion of value-based insurance design increase benefits from US health care without increasing costs? Evidence from a computer simulation modelReducing Medication Costs to Prevent Cardiovascular Disease: A Community Guide Systematic ReviewFinancial incentive increases CPAP acceptance in patients from low socioeconomic backgroundChanges in drug utilization during a gap in insurance coverage: an examination of the medicare Part D coverage gapA blueprint for pharmacy benefit managers to increase valueAdherence to Antihypertensive Therapy.Impact of pharmacy benefit design on prescription drug utilization: a fixed effects analysis of plan sponsor data.Building a value-based approach to biologic drugs.Costs and benefits of free medications after myocardial infarction.Characterizing weekly self-reported antihypertensive medication nonadherence across repeated occasions.Trends in patient cost sharing for clinical services used as quality indicators.Does a Free Office Visit Affect Primary Care-Seeking Behavior? A Study of New Exchange Health Plan Enrollees in MississippiMeasuring concurrent adherence to multiple related medicationsImpact of the change of copay policy in Medicare Part D on zoster vaccine uptake among Medicare beneficiaries in a managed care organization.Lower copay and oral administration: predictors of first-fill adherence to new asthma prescriptions.Prescription copay reduction program for diabetic employees: impact on medication compliance and healthcare costs and utilization.Partial compliance with antipsychotics increases mental health hospitalizations in schizophrenic patients: analysis of a national managed care database.The h-e-B value-based health management program: impact on asthma medication adherence and healthcare cost.Medication adherence: a call for actionA retrospective cohort study of the potency of lipid-lowering therapy and race-gender differences in LDL cholesterol control.Reducing cancer costs and improving quality through collaboration with payers: a proposal from the Florida society of clinical oncologyNonlinear pricing in drug benefits and medication use: the case of statin compliance in Medicare Part D.Hospitalizations and deaths among adults with cardiovascular disease who underuse medications because of cost: a longitudinal analysis.Increasing time costs and copayments for prescription drugs: an analysis of policy changes in a complex environment.An evaluation on the effect of the copayment waiver policy for Korean hospitalized children under the age of six.An evaluation of the impact of patient cost sharing for antihypertensive medications on adherence, medication and health care utilization, and expenditures.How patient cost-sharing trends affect adherence and outcomes: a literature review.Value-Based Benefit Design to Improve Medication Adherence for Employees with Anxiety or Depression.Value-based insurance design: more health at any price.Does medication adherence following a copayment increase differ by disease burden?The introduction of generic aromatase inhibitors and treatment adherence among Medicare D enrollees.Medicare Part D's effect on the under- and overuse of medications: a systematic review.The Impact of a Tiered Network on Hospital Choice.Potential Health Implications of Medication Therapy Management Eligibility Criteria in the Patient Protection and Affordable Care Act Across Racial and Ethnic Groups.Quality of Antiepileptic Treatment Among Older Medicare Beneficiaries With Epilepsy: A Retrospective Claims Data Analysis.The VALUE Framework: training residents to provide value-based care for their patientsEvaluation of the diabetes health plan to improve diabetes care and prevention.Steering patients to safer hospitals? The effect of a tiered hospital network on hospital admissionsA controlled trial of value-based insurance design - the MHealthy: Focus on Diabetes (FOD) trialRationale and design of the Post-MI FREEE trial: a randomized evaluation of first-dollar drug coverage for post-myocardial infarction secondary preventive therapies
P2860
Q21144630-4179A957-C190-4B2C-9EC4-4A136543C11DQ26775544-65FD5EC8-18B3-4DD8-A4E6-003C776E6EC2Q28382933-91A3BC97-44FB-4E52-8064-6E961DA7EE65Q28476575-672149FA-D8B4-438E-853B-AEFD51CC70F1Q28766235-0D80FB22-52B1-4C55-B3D1-0274F88F868CQ30240726-D54AD611-1CC5-402C-A540-7D420B849CA9Q33404862-14957CFA-0993-4A35-A13C-C9DB6CF581E3Q33561288-1B5DA5E4-0E7D-4702-BB9C-2AC8110487AFQ33585275-513648AD-8235-4DDF-96AB-B6D6385DA3BFQ33604932-0FB76A8F-86BB-4F81-BA75-C1965E16AC51Q33730870-7E8CF6B3-71BA-48F5-944A-F2335BF0309FQ33795964-36EA065C-EA75-4F45-A4B2-0CBFED14115AQ33866078-25D1A5EC-5648-47BA-97D9-A64B3540186BQ33922949-DBBF4C4E-9FDC-4A27-96AD-D62F0110D05EQ33932136-274E3829-6345-4E89-8BF2-6DDE3D03CF50Q33932355-03D2DF0C-E786-44FD-A3C1-7A50B5C0B58FQ33932365-A7B52072-A572-403B-B980-B8F995B3A028Q33932497-64903B66-879E-4680-8C6E-D159EEB54546Q34008160-59326696-C7EC-4B25-A329-3A0A0DBA8A6CQ34036014-504E52C7-C5CF-4B9C-B39C-6AB5A99F08B8Q34114926-B3CB5354-7ED7-469E-B343-040CD5A09146Q34509195-9A861822-66A7-416C-83CE-3E1AA90EEB27Q34556420-018D0A71-9014-4683-BF9B-675C8E1CB2C1Q34927764-EE63EBCC-24C4-49F1-BABB-A556A556C23CQ35577287-65304983-5512-48C7-A3B8-9E9F23622D9FQ35716882-416137A5-05E5-4A83-90AC-27EF0901B592Q35752951-FA2CBFF9-C7A8-4093-8EB1-27C63DB1FF8BQ36051898-7D85DC46-E8FF-4E21-9E29-61E42AF67953Q36085479-1C4B8E06-BD8F-498A-8B1E-FF142F84ED83Q36085521-F2A41194-380E-4DA0-A578-E174BAD7F38EQ36087210-EFE5B62D-E520-4BB2-BD66-9EEE952A4714Q36105740-5119EE80-CFE1-4166-A630-EE552E2F2E15Q36144468-12C73E7B-F1C8-408D-BDCC-00AD405E39CDQ36243328-6BD1090E-7053-4631-AA5F-A969367559B0Q36355039-81278353-AAF5-42AD-84CD-88DDFE5A0099Q36447237-B7A67CA5-A874-49F3-824A-8CB62C689157Q36581419-3B5DDB6F-DB9B-4623-AE00-1BE5B60A3F53Q37124421-28EC9F32-53B3-4C48-A472-97FA2A081034Q37169330-84CCCF7C-D0F4-4033-8068-6FE12E97C665Q37229332-BE8006CE-D7FF-4DC6-9508-ECE3BD60593D
P2860
Impact of decreasing copayments on medication adherence within a disease management environment.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Impact of decreasing copayment ...... isease management environment.
@en
Impact of decreasing copayment ...... isease management environment.
@nl
type
label
Impact of decreasing copayment ...... isease management environment.
@en
Impact of decreasing copayment ...... isease management environment.
@nl
prefLabel
Impact of decreasing copayment ...... isease management environment.
@en
Impact of decreasing copayment ...... isease management environment.
@nl
P2093
P356
P1433
P1476
Impact of decreasing copayment ...... isease management environment.
@en
P2093
A Mark Fendrick
Allison B Rosen
Arnold Wegh
Iver A Juster
Kristina Yu-Isenberg
Mayur R Shah
Michael C Sokol
Michael E Chernew
Stephen N Rosenberg
P304
P356
10.1377/HLTHAFF.27.1.103
P407
P577
2008-01-01T00:00:00Z